Drug Profile
Research programme: viral vaccines - Pharos Biologicals
Latest Information Update: 04 Sep 2023
Price :
$50
*
At a glance
- Originator Pharos Biologicals
- Class DNA vaccines; Influenza virus vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Dengue; Influenza virus infections; Zika virus infection
Most Recent Events
- 04 Sep 2023 Discontinued - Preclinical for Zika virus infection in USA (unspecified route)
- 04 Sep 2023 Discontinued for Dengue in USA (unspecified route)
- 04 Sep 2023 Discontinued for Influenza virus infections in USA (unspecified route)